Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR 0.0070
0.00 (0.00%)
Sep 2, 2026, 4:20 PM CET
Fidia Employees
Fidia had 146 employees as of December 31, 2025. The number of employees decreased by 13 or -8.18% compared to the previous year.
Employees
146
Change
-13
Growth
-8.18%
Revenue / Employee
€209,329
Profits / Employee
€7,116
Market Cap
3.50M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 146 | -13 | -8.18% |
| Jun 30, 2025 | 140 | - | - |
| Dec 31, 2024 | 159 | -34 | -17.62% |
| Dec 31, 2023 | 193 | -4 | -2.03% |
| Dec 31, 2022 | 197 | - | - |
| Jun 30, 2020 | 289 | -42 | -12.69% |
| Mar 31, 2020 | 299 | -32 | -9.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Interpump Group | 9,712 |
| Biesse | 3,601 |
| SIT S.p.A. | 1,916 |
| Tesmec | 937 |
| ILPRA | 422 |
| Marzocchi Pompe | 249 |
| OSAI Automation System | 222 |
| Clabo | 148 |
Fidia News
- 2 hours ago - US medical groups urge people to get flu and Covid shots in counter to Trump guidance - The Guardian
- 3 hours ago - Johnson & Johnson Shares Jump Toward the Record High After FDA Approval; UBS Lifts Target to $320 - International Business Times (Australia)
- 3 hours ago - UTHR Looks 20.1% Overvalued on GF Value⢠as FDA Expands Tyvaso Label - GuruFocus
- 3 hours ago - Altria sues FDA over tobacco product review system - Reuters
- 3 hours ago - Scholar Rock (SRRK) Gains FDA Fast Track for Apitegromab Amid High Price-to-Sales Valuation - GuruFocus
- 4 hours ago - SciSparc Subsidiary Pursues FDA Orphan Drug Status For Tourette Syndrome Drug - Nasdaq
- 5 hours ago - UTHR Looks 20.1% Overvalued on GF Value⢠as FDA Review Progresses - GuruFocus
- 5 hours ago - Scholar Rock: FDA Grants Fast Track And Orphan Drug Designations To Apitegromab - Nasdaq